Sernova (TSE:SVA)
TSX:SVA
Want to see TSE:SVA full AI Analyst Report?
SVA Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.22
Previous CloseN/A
Volume71.45K
Average Volume (3M)125.66K
Market Cap
C$53.90M
Enterprise ValueC$70.87M
Total Cash (Recent Filing)C$576.22K
Total Debt (Recent Filing)C$17.55M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Jun 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding347,726,350
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformSernova’s Cell Pouch System is a proprietary implantable platform built to host therapeutic cells and sustain long-term function. As a platform play in regenerative medicine, it can create durable differentiation versus drugs if clinically validated, supporting recurring therapeutic value for chronic diseases.
Moderating Cash BurnTTM operating cash outflow decreased versus prior years, indicating management has cut near-term cash consumption. Sustained moderation in burn rate materially extends runway to reach clinical inflection points, reduces immediate refinancing pressure, and improves the odds of funding through milestone-driven financing.
Improving Loss TrendSmaller net losses in 2025 and TTM versus prior years suggest better cost control or operational progress. A continuing trend of reduced losses can preserve cash, lower future financing needs, and increase the company's ability to execute clinical programs before needing large dilutive raises.
Bears Say
Pre-revenueThe company remains pre-revenue with zero sales across annual periods and TTM, meaning all R&D and operations depend on external funding. Long-term viability hinges on clinical and regulatory success and the ability to convert the platform into commercial products, raising execution and financing risk.
Weak Balance SheetDeeply negative equity combined with a sharp increase in debt (~$17.5M TTM) creates elevated balance-sheet risk. This limits strategic flexibility, heightens refinancing and covenant risk, and increases the likelihood of future dilution or onerous financing terms if development timelines slip.
Negative Cash GenerationOperating and free cash flow remain materially negative with declining FCF growth, reflecting structural cash-generation shortfalls. Ongoing burn necessitates recurrent external capital, elevating dilution and execution risk and constraining the company’s ability to advance multiple programs or respond to setbacks.
Sernova News
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.12 and its highest was C$0.22 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$53.90M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 12, 2026 which is in 23 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 13, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Overvalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.01.
How many shares outstanding does Sernova have?
Sernova has 347,726,350 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―
Options Prices
Currently, No data available
---